Indian Journal of Nuclear Medicine

CASE REPORT
Year
: 2022  |  Volume : 37  |  Issue : 1  |  Page : 64--67

Utero-Ovarian involvement in non-hodgkin's lymphoma on 18F-Fluorodeoxyglucose positron emission tomography/computed tomography: A case series and literature review


Vivek Kumar Saini1, Alen Elias Mammoottil1, Aftab Hassan Nazar1, Punita Pavecha2, Manish Ora1, Sanjay Gambhir1,  
1 Department of Nuclear Medicine, SGPGIMS, Lucknow, Uttar Pradesh, India
2 Department of Hematology, KGMU, Lucknow, Uttar Pradesh, India

Correspondence Address:
Dr. Manish Ora
Department of Nuclear Medicine, SGPGIMS, Lucknow - 226 014, Uttar Pradesh
India

Abstract

Lymphomas are common solid malignancies. They are associated with substantial morbidity and mortality. Hodgkin's lymphoma (HL) and Non-HL (NHL) are subtypes of lymphoma. Lymph nodes are the most common site of involvement, though practically any organ may be involved. NHL has preponderance for extranodal involvement. Primary uterine and ovarian NHL is scarce. However, in advanced systemic disease, secondary utero-ovarian involvement may be seen. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is a pivotal imaging modality in lymphomas. It abets in pretreatment staging, posttherapy restaging, and surveillance. We present three stage-IV NHL cases with secondary utero-ovarian involvement. FDG PET/CT as a baseline imaging modality established the disease burden and organ involvement.



How to cite this article:
Saini VK, Mammoottil AE, Nazar AH, Pavecha P, Ora M, Gambhir S. Utero-Ovarian involvement in non-hodgkin's lymphoma on 18F-Fluorodeoxyglucose positron emission tomography/computed tomography: A case series and literature review.Indian J Nucl Med 2022;37:64-67


How to cite this URL:
Saini VK, Mammoottil AE, Nazar AH, Pavecha P, Ora M, Gambhir S. Utero-Ovarian involvement in non-hodgkin's lymphoma on 18F-Fluorodeoxyglucose positron emission tomography/computed tomography: A case series and literature review. Indian J Nucl Med [serial online] 2022 [cited 2022 Oct 6 ];37:64-67
Available from: https://www.ijnm.in/text.asp?2022/37/1/64/340884


Full Text



 Introduction



Lymphoma is a malignant proliferation of lymphoid tissue and frequently commences from Lymph nodes (LNs). Lymphomatous involvement in virtually any organ is described. Extranodal lymphoma (ENL) is the infiltration of malignant lymphomatous cells in organs other than LNs. Approximately one-fourth of the lymphomas arise in extranodal organs. The most frequently involved organ system in ENL is the gastrointestinal tract (The stomach is the most typical site), followed by Waldeyer's ring, lung, liver, spleen, bone, and skin.[1] Primary ENL is intriguing as it may have distinct clinicopathologic features, association with underlying immunodeficiency syndromes, autoimmune diseases, and infections.[2] Primary Non-Hodgkin's lymphomas (NHLs) of the female genital tract are uncommon. Only 1.5% of all ENL originate in the female genital tract, with ovaries being the most common site.[3] Secondary involvement of the female genital system is more common. A patient may present with gynecological symptoms or remain asymptomatic. Conventional cross-sectional imaging has several constraints in assessing lymphomas. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is a hybrid imaging modality and has become the standard of care in HL and NHL.[4] It accurately identifies disease burden and organ involvement. This case review presents the three NHL patients with secondary involvement of the uterus and adnexa.

 Case Reports



Case 1

A 60-year-old female presented with complaints of fever for 1 month. The pain was progressive and associated with an inability to walk. On examination, there was a large lump in the right lumbar region. She was menopausal for 12 years and had no significant gynecological history. Her routine blood investigation revealed anemia (Hb-7.6 g/dl), leukocytosis (15,400/uL), and raised serum LDH levels (1140 u/L). Ultrasound (USG) abdomen showed enlarged retroperitoneal LNs. Guided histopathology showed high-grade lymphoma. Immunohistochemistry was noncontributory due to large areas of necrosis and marked degenerative changes. A baseline FDG PET/CT was done [Figure 1]. She received three cycles of the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Her interim FDG PET/CT after three cycles of chemotherapies revealed a partial response to the treatment (not shown).{Figure 1}

Case 2

An 11-year-old girl presented with swelling on the left side of the neck for 6 months. She had no associated fever or weight loss. On examination, the patient had palpable, firm enlarged cervical LNs. She has not attained menarche. She had no significant gynecological complaints. Her biochemical investigations were unremarkable. CT suggested bilateral enlarged cervical LNs. Excision biopsy was suggestive of NHL (diffuse large B cell lymphoma). Her baseline FDG PET/CT revealed stage-IV disease [Figure 2].{Figure 2}

Case 3

A 60-year-old female presented with swelling on both sides of the neck for 3 months. It was associated with on and off fever and generalized weakness. On examination, she had multiple enlarged bilateral cervical LNs. Biopsy was suggestive of anaplastic large cell lymphoma. The patient was given three cycles of R-CHOP. However, no clinical response was noted. She was referred to our institute for further management. She had no gynecological complaints. LDH levels were significantly raised (825 u/L). The rest of the biochemical investigations were unremarkable. HPE was suggestive of diffuse large B cell lymphoma (anaplastic variant). On immunohistochemistry, tumor cells were positive for CD-20 and CD-3. FDG PET/CT was done for restaging [Figure 3]. The patient was lost to follow-up during the COVID-19 pandemic.{Figure 3}

 Discussion



Lymphomas are common tumors and collectively rank fifth in cancer in incidence and mortality. They are a heterogeneous group of diseases ranging from indolent malignancies to rapidly growing and highly aggressive tumors. The prevalence of NHL has been increasing during the past two decades.[5],[6] NHLs themself are varied groups based on clinical presentation, morphological appearance, and response to therapy. Primary lymphomas involving the gynecologic tract are very uncommon. Most of these are NHL, and the most common subtype is diffuse large B-cell.[7],[8] The secondary lymphomatous involvement of the uterus and ovaries is usually associated with disseminated disease.[9]

Cross-sectional anatomical imaging plays an essential role in the evaluation of gynecological malignancy. They also access other pelvis and abdominal organs. In utero-ovarian lymphoma, CT shows well-demarcated hypodense lesions with mild contrast enhancement.[10] On magnetic resonance imaging, uterine lymphoma exhibits homogeneous hypointense signal on T1-weighted images and relatively hyperintense on T2-weighted images. It presents as diffuse and uniform enlargement of the uterine corpus and cervix. The endometrium and cervical epithelium remain unremarkable. However, in some cases, it is indistinguishable from carcinoma.[11] The limitations of these imagings are the limited imaging area and low specificity in accessing nonenlarged pathologies.

FDG PET/CT the cornerstone of imaging in both HL and NHL.[12] It plays an essential role in staging, restaging, prognostication, planning appropriate treatment strategies, monitoring therapy, and detecting recurrence.[13] The advantage of PET over conventional imaging techniques is to access nonenlarged disease involvement. Another crucial aspect is differentiating between viable tumor, necrosis, or fibrosis in residual mass often present after treatment.[14] Due to the very low incidence of primary uterine lymphoma, scarce literature is available for management. It involves hysterectomy and bilateral salpingo-oophorectomy, chemotherapy, irradiation, or a combination of these.[15] All advanced cases with secondary utero-ovarian involvement are treated with systemic chemotherapy. All three patients had stage-IV disease at presentation, and they underwent systemic chemotherapy. These cases show the rare asymptomatic involvement of the uterus and ovaries in disseminated NHL. FDG PET/CT could identify all the sites of involvement in one scan, thus helped in staging and prognostication.

 Conclusion



Primary lymphomas of the female genital organs are rare. Even secondary involvement is not well discussed in the literature. FDG PET/CT is a noninvasive imaging modality that discloses disease extent and asymptomatic organ involvement. It helps in staging, prognostication, guiding treatment, and response evaluation.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics 2010;30:269-91.
2Ferry JA. Extranodal lymphoma. Arch Pathol Lab Med 2008;132:565-78.
3Upanal N, Enjeti A. Primary lymphoma of the uterus and cervix: Two case reports and review of the literature. Aust N Z J Obstet Gynaecol 2011;51:559-62.
4Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009;50 Suppl 1:21S-30S.
5Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
6Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76.
7Trenhaile TR, Killackey MA. Primary pelvic non-Hodgkin's lymphoma. Obstet Gynecol 2001;97:717-20.
8Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein's Pathology of the Female Genital Tract. 7th ed. Springer Nature Switzerland AG: Springer International Publishing; 2019. Available from: https://www.springer.com/gp/book/9783319463339. [Last accessed on 2021 Jun 02].
9Frey NV, Svoboda J, Andreadis C, Tsai DE, Schuster SJ, Elstrom R, et al. Primary lymphomas of the cervix and uterus: The University of Pennsylvania's experience and a review of the literature. Leuk Lymphoma 2006;47:1894-901.
10Ferrozzi F, Catanese C, Uccelli M, Bassi P. Linfoma ovarico. Aspetti con ecografia, Tomografia Computerizzata e Risonananza Magnetica [Ovarian lymphoma. Findings with ultrasonography, computerized tomography and magnetic resonance]. Radiol Med 1998;95:493-7.
11Kawakami S, Togashi K, Kojima N, Morikawa K, Mori T, Konishi J, et al. MR appearance of malignant lymphoma of the uterus. J Comput Assist Tomogr 1995;19:238-42.
12Singh V, Kumar A, Singh P, Ora M, Gambhir S. Extensive extranodal involvement in a case of Non-Hodgkin's Lymphoma with sparing of lymph nodes and lymphatic organs. Asia Ocean J Nucl Med Biol 2021;9:39-44.
13D'souza MM, Jaimini A, Bansal A, Tripathi M, Sharma R, Mondal A, et al. FDG-PET/CT in lymphoma. Indian J Radiol Imaging 2013;23:354-65.
14Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33.
15Shen CJ, Tsai EM, Tsai KB, Wu CH, Hsu SC. Primary T-cell lymphoma of the uterine corpus. Kaohsiung J Med Sci 2007;23:138-41.